Report Description Table of Contents Introduction And Strategic Context The Global HER2 Positive Gastric Cancer Market expanding at 6.8% CAGR, forecast to grow from USD 3.7 billion in 2024 to USD 5.5 billion by 2030, driven by targeted therapy, market growth, treatment landscape, epidemiology, competitive landscape, emerging drugs as reported by Strategic Market Research. HER2 positive gastric cancer is a biologically distinct subtype of gastric cancer characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2). While HER2 positivity is more commonly associated with breast cancer, it has emerged as a crucial biomarker in gastric and gastroesophageal junction (GEJ) adenocarcinomas. This biomarker now defines treatment eligibility for targeted therapies such as trastuzumab, trastuzumab deruxtecan , and newer agents under investigation. What makes this market strategically relevant is the confluence of precision oncology, growing biomarker testing, and unmet clinical needs in advanced gastric cancer care. Gastric cancer remains the fifth most common cancer globally and the third leading cause of cancer death. Yet, only around 15–20% of gastric tumors express HER2 — creating a highly defined but clinically urgent niche. As diagnostics improve, HER2 testing is increasingly standardized at diagnosis, particularly in major markets like the U.S., Japan, China, and South Korea. That standardization is enabling earlier initiation of HER2-targeted therapies — a shift from the traditional chemotherapy-first model. The treatment landscape is also moving beyond trastuzumab. Antibody-drug conjugates (ADCs), bispecific antibodies, and HER2-directed immunotherapies are being tested in first-line and refractory settings. These pipeline developments reflect a broader industry shift: from broad-spectrum cytotoxic agents to precision-targeted combinations. Stakeholders across the board are positioning around this shift. Pharmaceutical companies are competing to introduce next-generation HER2 inhibitors. Diagnostic firms are partnering with oncology networks to expand HER2 IHC and FISH testing access. Healthcare systems are adjusting reimbursement structures to include high-cost biologics, while clinical oncologists are reshaping protocols around biomarker-first treatment planning. Comprehensive Market Snapshot The Global HER2 Positive Gastric Cancer Market is projected to grow at a CAGR of 6.8%, expanding from USD 3.7 billion in 2024 to USD 5.5 billion by 2030. Asia Pacific (APAC) leads the global market with 48% share, valued at USD 1.78 Billion in 2024, supported by a large patient base, improving oncology access, and rapid adoption of targeted therapies, and it is also the fastest expanding region with a CAGR of 9.3%, driven by healthcare infrastructure upgrades and increasing biomarker testing. USA represents a significant 36% share, reaching USD 1.33 Billion in 2024, driven by strong reimbursement systems and early adoption of biologics, and is projected to grow at a CAGR of 5.7% with continued innovation in targeted therapies. Europe holds 23% share, accounting for USD 0.85 Billion in 2024, supported by established treatment guidelines and access to oncology care, and is expected to grow steadily at a CAGR of 4.6%. Regional Insights Asia Pacific (APAC) accounted for the largest market share of 48% in 2024. Asia Pacific (APAC) is expected to expand at the fastest CAGR of 9.3% during 2024–2030. By Therapy Type Targeted Monoclonal Antibodies dominate the segment with 48% share, translating to USD 1.78 Billion in 2024, supported by their role as first-line standard therapy and strong clinical familiarity across oncology settings. Antibody-Drug Conjugates (ADCs) emerge as the fastest-growing category with a 2024 value of USD 1.00 Billion and a projected high-growth trajectory, driven by superior efficacy in resistant cases and increasing adoption in later-line treatment. Immunotherapy-Based Combinations account for USD 0.48 Billion in 2024, gaining attention due to synergistic outcomes in PD-L1 positive patients and ongoing clinical trial expansion. Tyrosine Kinase Inhibitors (TKIs) contribute USD 0.44 Billion in 2024, with gradual uptake supported by combination strategies and use in patients unsuitable for biologics. By Line of Treatment First-Line Treatment holds the largest share at 55%, equivalent to USD 2.04 Billion in 2024, driven by trastuzumab-based regimens remaining the standard initial therapy. Second-Line Treatment is the fastest-growing segment with a 2024 value of USD 1.11 Billion and strong growth momentum, fueled by rising resistance rates and increasing use of ADCs and novel agents. Third-Line & Beyond accounts for USD 0.56 Billion in 2024, supported by expanding treatment options and personalized therapy approaches based on evolving HER2 expression. By Diagnostic Modality Immunohistochemistry (IHC) leads with 60% share, representing USD 2.22 Billion in 2024, due to its affordability, accessibility, and role as the primary screening tool. Next-Generation Sequencing (NGS) is the fastest-growing modality with a 2024 value of USD 0.56 Billion, driven by increasing adoption in precision oncology and its ability to detect co-mutations influencing treatment response. Fluorescence In Situ Hybridization (FISH) contributes USD 0.93 Billion in 2024, maintaining importance as a confirmatory method in ambiguous cases. By Distribution Channel Hospital Pharmacies dominate with 65% share, equating to USD 2.41 Billion in 2024, supported by the need for controlled administration and reimbursement management of complex biologics. Infusion Centers are the fastest-growing channel with a 2024 value of USD 0.56 Billion, driven by increasing use of ADCs requiring monitored delivery environments. Specialty Pharmacies account for USD 0.74 Billion in 2024, gaining traction with the expansion of outpatient oncology care and specialty drug distribution systems. Strategic Questions Driving the HER2 Positive Gastric Cancer Market What therapies, diagnostic approaches, and patient populations are explicitly included within the HER2 positive gastric cancer market, and which treatment modalities fall outside its scope? How does the HER2 positive gastric cancer market structurally differ from broader gastric cancer, oncology biologics, and immunotherapy markets? What is the current and projected market size for HER2 positive gastric cancer, and how is revenue distributed across therapy classes such as monoclonal antibodies, ADCs, and combination regimens? How is revenue currently split between first-line trastuzumab-based therapies, later-line ADCs, and emerging immunotherapy combinations, and how is this mix expected to evolve? Which treatment segments (first-line, second-line, third-line and beyond) contribute the largest share of revenue, and which are expected to grow the fastest? Which therapy categories generate the highest margins, particularly between established biologics and next-generation targeted therapies? How does demand vary across early-stage versus advanced/metastatic HER2 positive gastric cancer patients, and how does this influence therapy adoption? How are treatment pathways evolving with respect to sequencing between monoclonal antibodies, ADCs, TKIs, and immunotherapy combinations? What role do treatment duration, resistance development, and therapy switching play in driving overall market growth? How are HER2 testing rates, diagnostic accuracy, and repeat biopsy practices influencing eligible patient pools? What clinical or regulatory challenges are limiting adoption of newer therapies, particularly in emerging markets? How do pricing pressures, reimbursement frameworks, and access disparities affect uptake of high-cost biologics and ADCs? How robust is the current pipeline of HER2-targeted therapies, and which novel mechanisms are expected to redefine treatment standards? Will pipeline innovations expand the treatable patient population or primarily intensify competition within existing therapy lines? How are advancements in drug delivery systems, such as ADC payload optimization, improving clinical outcomes and safety profiles? How will patent expirations of key biologics impact competitive dynamics and pricing within the market? What role will biosimilars of trastuzumab and other HER2 therapies play in improving access while driving price erosion? How are leading pharmaceutical companies positioning their HER2 gastric cancer portfolios to compete across different lines of therapy? Which geographic markets, particularly APAC, USA, and Europe, are expected to outperform global growth, and what factors are driving regional differences? How should stakeholders prioritize investment across therapy classes, treatment lines, and regions to maximize long-term value in the HER2 positive gastric cancer market? Segment-Level Insights and Market Structure HER2 Positive Gastric Cancer Market The HER2 positive gastric cancer market is organized across therapy classes, treatment lines, diagnostic approaches, and distribution pathways, each reflecting variations in clinical complexity, patient eligibility, and care delivery settings. These segments differ in their contribution to total market value, pace of innovation, and competitive intensity. Market evolution is strongly influenced by biomarker-driven treatment selection, resistance patterns, and the increasing shift toward precision oncology. Therapy Type Insights Targeted Monoclonal Antibodies Targeted monoclonal antibodies form the clinical backbone of HER2 positive gastric cancer treatment, particularly in first-line settings. Their continued dominance is linked to established treatment protocols and widespread physician familiarity. These therapies function by directly inhibiting HER2 signaling pathways, thereby slowing tumor growth. From a market standpoint, they represent a stable and high-volume segment, supported by strong guideline inclusion and consistent demand across major regions. Their role is gradually being complemented by newer therapies rather than replaced, ensuring sustained relevance. Antibody-Drug Conjugates (ADCs) Antibody-drug conjugates represent one of the most dynamic areas of innovation within this market. By combining targeted HER2 binding with cytotoxic payload delivery, ADCs offer a more precise and potent therapeutic approach. Their adoption is accelerating, particularly in patients who develop resistance to initial therapies. Clinically, they are redefining expectations in later-line treatment by improving response rates and extending survival outcomes. From a market perspective, ADCs are rapidly gaining share and are expected to significantly influence future revenue distribution. Tyrosine Kinase Inhibitors (TKIs) Tyrosine kinase inhibitors occupy a more selective position within the treatment landscape. These agents act on intracellular signaling mechanisms associated with HER2 and related pathways. Their use is often considered in specific patient populations, including those unable to tolerate biologic therapies or as part of combination regimens. Although currently a smaller segment, TKIs are gaining strategic importance as research explores their role in overcoming resistance and enhancing treatment flexibility. Immunotherapy-Based Combinations Immunotherapy combinations integrating checkpoint inhibitors with HER2-targeted agents are emerging as an important frontier. These approaches aim to activate the immune system while simultaneously targeting tumor-specific pathways. Their clinical relevance is particularly notable in patients with elevated PD-L1 expression. While still evolving, this segment is expected to expand as ongoing trials validate their efficacy, positioning immunotherapy combinations as a key growth driver in the coming years. Line of Treatment Insights First-Line Treatment First-line therapy represents the largest and most established segment, typically centered around trastuzumab combined with chemotherapy. This stage of treatment captures the highest patient volume, as it serves as the initial intervention following diagnosis. Its dominance is reinforced by standardized clinical guidelines and consistent global adoption. From a market perspective, first-line therapy contributes significantly to baseline revenue due to its broad applicability. Second-Line Treatment Second-line therapy is gaining increasing importance as disease progression and resistance to initial treatment become more common. This segment is characterized by the introduction of newer, more advanced therapies such as ADCs. Clinicians are increasingly shifting toward these options to achieve better disease control after first-line failure. As a result, this segment is experiencing strong growth momentum and is becoming a key area of competitive differentiation. Third-Line and Beyond Later-line treatment represents a more specialized segment focused on heavily pre-treated patients. Therapeutic decisions in this stage are highly individualized, often guided by prior treatment history and evolving biomarker status. Although smaller in patient volume, this segment reflects high clinical complexity and increasing reliance on innovative therapies. Its importance is growing as more treatment options become available for advanced disease stages. Diagnostic Modality Insights Immunohistochemistry (IHC) Immunohistochemistry serves as the primary screening method for identifying HER2 expression. Its widespread use is driven by cost-effectiveness, accessibility, and established integration into diagnostic workflows. As the first step in determining treatment eligibility, IHC plays a foundational role in shaping the addressable patient population. It remains the most commonly utilized diagnostic modality across both developed and emerging markets. Fluorescence In Situ Hybridization (FISH) FISH is primarily used as a confirmatory technique, particularly in cases where initial test results are inconclusive. It provides a more definitive assessment of HER2 gene amplification, ensuring accurate patient classification. Although used less frequently than IHC, it maintains critical importance in refining diagnostic precision and supporting treatment decisions in borderline cases. Next-Generation Sequencing (NGS) Next-generation sequencing is emerging as a more advanced diagnostic approach, offering deeper insights into tumor biology. Beyond HER2 status, it enables identification of additional genetic alterations that may influence treatment response or resistance. Its adoption is increasing in specialized oncology centers, reflecting a broader shift toward comprehensive molecular profiling and personalized treatment strategies. Distribution Channel Insights Hospital Pharmacies Hospital pharmacies represent the central distribution channel for HER2 positive gastric cancer therapies. Their dominance is driven by the complexity of treatment regimens, particularly for injectable biologics and infusion-based therapies. These settings are closely integrated with oncology care teams, enabling coordinated treatment delivery and monitoring. As a result, hospital pharmacies account for a substantial portion of overall drug distribution. Specialty Pharmacies Specialty pharmacies are becoming increasingly relevant, particularly for managing high-cost and targeted therapies. They provide specialized services such as patient support programs, adherence monitoring, and reimbursement coordination. Their role is expanding alongside the growth of outpatient oncology care, making them an important component of the evolving distribution landscape. Infusion Centers Infusion centers are gaining importance as more therapies require controlled administration outside traditional hospital settings. These centers serve as an intermediary between innovation and patient access, particularly for ADCs and other complex biologics. Their growth reflects a broader trend toward decentralized cancer care and improved patient convenience. Segment Evolution Perspective The HER2 positive gastric cancer market is undergoing a gradual but meaningful transformation. Established therapies continue to anchor current treatment practices, ensuring stability in baseline demand. At the same time, next-generation approaches such as ADCs and immunotherapy combinations are reshaping clinical expectations and competitive dynamics. Parallel to therapeutic innovation, diagnostic capabilities are advancing toward more precise and repeatable testing, enabling better patient selection and treatment optimization. Distribution models are also adapting, with a shift toward outpatient care and specialized delivery channels. Together, these factors are redefining how value is distributed across segments, with future growth expected to be driven by innovation-led therapies, personalized treatment strategies, and expanding access to advanced oncology care. Market Segmentation And Forecast Scope The HER2 positive gastric cancer market is evolving across multiple layers — not just clinically, but commercially as well. Each segment reflects how treatment strategies are shifting in real-world oncology settings. From therapy innovation to diagnostic precision, these dimensions are quietly redefining how stakeholders approach this space. By Therapy Type Targeted Monoclonal Antibodies : This remains the backbone of treatment, with trastuzumab continuing to anchor first-line regimens. In 2024, this segment holds around 48% of total market revenue. Its dominance comes from strong clinical familiarity and guideline support across major oncology markets. Antibody-Drug Conjugates (ADCs) : This is where things are shifting fast. Agents like trastuzumab deruxtecan are changing expectations in later-line therapy. Clinicians are increasingly leaning toward ADCs once resistance to first-line therapy sets in, mainly because of their targeted delivery and improved response depth. Tyrosine Kinase Inhibitors (TKIs) : While still a smaller segment, TKIs are being explored for combination strategies. Their role is evolving, particularly in patients who may not tolerate biologics well. Immunotherapy-Based Combinations : Checkpoint inhibitors combined with HER2-targeted therapies are gaining traction. These combinations are being tested aggressively in trials, especially for patients with high PD-L1 expression. By Line of Treatment First-Line Treatment : This segment continues to lead, supported by trastuzumab plus chemotherapy regimens. It’s still the standard starting point in most treatment pathways. Second-Line and Beyond : This is where momentum is building. As trastuzumab resistance becomes more common, demand for next-line therapies is rising sharply. ADCs and newer targeted agents are increasingly being positioned here. Another shift worth noting — HER2 expression isn’t always stable. It can change over time, especially after treatment exposure. That’s pushing oncologists toward repeat testing and more personalized, line-specific treatment decisions. By Diagnostic Modality Immunohistochemistry (IHC) : The most widely used method due to its affordability and accessibility. It serves as the initial screening tool in most healthcare settings. Fluorescence In Situ Hybridization (FISH) : Typically used for confirmation in borderline cases. It remains the gold standard when results are ambiguous. Next-Generation Sequencing (NGS) : Still emerging but gaining relevance. Advanced oncology centers are starting to use NGS to uncover co-mutations that may influence HER2 response or resistance patterns. Diagnostic companies are also getting smarter. Bundled HER2 testing kits — covering both gastric and breast cancers — are becoming more common, especially in community oncology networks. By Distribution Channel Hospital Pharmacies : This remains the dominant channel, largely because HER2 therapies are complex biologics requiring controlled administration and reimbursement tracking. Specialty Pharmacies : Gaining traction, particularly in the U.S. and Japan, where outpatient oncology care is expanding. Infusion Centers : Becoming increasingly important, especially for ADCs that require monitored delivery. These centers are emerging as a critical interface between therapy innovation and patient access. By Region North America : Strong adoption of advanced therapies and robust reimbursement frameworks continue to support market growth. Asia Pacific : A high-impact region driven by patient volume. Countries like Japan, China, and South Korea lead due to higher gastric cancer incidence and structured HER2 testing protocols. Europe : A stable but fragmented landscape. Western Europe shows strong adoption, while Eastern regions face access variability. Latin America and Middle East : Still developing in terms of diagnostics and access. That said, improving infrastructure could unlock meaningful growth over the next few years. Overall, segmentation in this market isn’t just about categorization — it’s becoming a strategic tool. Companies that align therapy innovation with diagnostic precision and access channels are likely to outperform. Market Trends And Innovation Landscape The HER2 positive gastric cancer market is no longer riding on trastuzumab alone. In fact, the innovation wave here is starting to mirror the complexity seen in breast cancer — with multiple drug classes, biomarker-guided regimens, and combination strategies competing for dominance. Antibody-Drug Conjugates Are Reshaping the Post-Trastuzumab Landscape The most disruptive trend right now is the clinical success of antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (T- DXd ). Unlike traditional HER2 inhibitors, these drugs deliver potent cytotoxics directly to tumor cells via HER2 targeting, minimizing collateral damage. Phase II and III studies have shown T- DXd improving progression-free survival (PFS) and overall survival (OS) in patients who’ve already failed trastuzumab. One oncologist in Singapore described ADCs as “the first real breakthrough we’ve had for HER2 positive gastric cancer beyond first-line.” These drugs are also being tested in combination with immune checkpoint inhibitors, opening up new dual-targeting frontiers. Next-Generation HER2 Inhibitors Are Targeting Resistance Pathways Several newer HER2 inhibitors, including reversible TKIs and bispecific antibodies, are in clinical trials aimed at overcoming acquired resistance. Resistance mechanisms in gastric cancer are different from breast cancer — often involving heterogeneity in HER2 expression or activation of bypass pathways like MET and EGFR. Developers are now testing combination regimens that include HER2 inhibition plus co-pathway blockade, hoping to increase durability of response. Agents like zanidatamab (a bispecific HER2 antibody) are showing promise in early-phase trials. Companion Diagnostics Are Becoming More Integrated — and More Digital Another important shift is happening at the diagnostic level. HER2 testing is becoming more streamlined, with digital pathology tools enabling automated scoring and remote interpretation of IHC slides. Some vendors are also integrating HER2 testing into broader NGS panels, allowing oncologists to capture HER2 status along with microsatellite instability (MSI), PD-L1, and tumor mutational burden (TMB) — all of which may influence treatment planning. In emerging markets, point-of-care HER2 assays are being piloted in regional cancer centers , especially in high-incidence geographies like China and South Korea. That decentralization could radically accelerate time-to-treatment. Immunotherapy Combinations Are Gaining Ground While checkpoint inhibitors alone haven’t shown strong efficacy in HER2 positive patients, combinations with HER2-targeted agents are being studied intensively. Trials like KEYNOTE-811 have already incorporated pembrolizumab into first-line trastuzumab-based regimens. The hypothesis is that HER2-targeting may boost antigen presentation, making tumors more responsive to immunotherapy. The next wave of approvals could involve multi-agent regimens — HER2 inhibition plus PD-1 blockade — setting a new treatment standard for newly diagnosed patients. Real-World Evidence Is Influencing Access Pathways Payers and health technology assessment (HTA) bodies are increasingly relying on real-world data (RWD) to make coverage decisions for high-cost therapies. Several registry-based studies in Japan and Europe are tracking long-term outcomes for patients on T- DXd or HER2-immunotherapy combinations. This is influencing reimbursement timelines and shaping national formulary updates — particularly in publicly funded systems. Competitive Intelligence And Benchmarking The HER2 positive gastric cancer market is shaped by a focused but aggressive group of biopharmaceutical companies — many of which originally built their HER2 portfolios around breast cancer. What sets them apart today isn’t just who entered the space first, but how they're adapting to the unique biology and treatment challenges of gastric tumors . Roche / Genentech Still seen as the foundational player in HER2 targeting, Roche’s trastuzumab remains the first-line standard across most markets. The company was quick to translate its breast cancer success into gastric indications, and continues to lead in terms of installed clinical use. That said, their innovation pace has slowed relative to newer entrants, and biosimilar competition is starting to erode margins in regions like Asia and Eastern Europe. Roche is banking on lifecycle management through fixed-dose combinations and subcutaneous formulations — but its dominance is no longer uncontested. AstraZeneca and Daiichi Sankyo This alliance has emerged as the most disruptive force in the market. Their antibody-drug conjugate, trastuzumab deruxtecan (T- DXd ) , has demonstrated strong efficacy in patients previously treated with trastuzumab, driving rapid uptake as a second-line therapy. AstraZeneca brings global commercialization muscle, while Daiichi provides deep ADC expertise — a rare pairing that is raising the bar for next-gen HER2 therapy. They’re also investing heavily in combination trials, targeting expansion into first-line settings and even HER2-low subtypes. Zymeworks A rising biotech contender, Zymeworks is pushing the envelope with zanidatamab , a bispecific antibody that binds to two different domains on HER2. Early data suggests potential activity in both high and heterogeneous HER2-expressing tumors , which are common in gastric cancer. The company is carving out a clear differentiation path through structural biology and is seen as a partner of interest for larger firms seeking access to gastric trials. Seagen (now part of Pfizer) Seagen , known for its ADC portfolio, is expanding its HER2 pipeline through internal candidates and licensing deals. With Pfizer now in control, the company may accelerate its push into HER2 positive GI cancers as part of a broader strategic pivot into oncology. Seagen’s modular linker-payload technology may also enable more tumor -specific delivery — an area where gastric cancer poses challenges due to tissue heterogeneity. Jiangsu Hengrui / Innovent Biologics In China, local pharmaceutical firms like Hengrui and Innovent are rapidly developing biosimilars and homegrown HER2 inhibitors tailored to regional clinical guidelines. They offer more affordable alternatives to Western therapies, and in some cases are developing novel combinations targeting HER2 plus EGFR or PD-1. These players are especially influential in Tier 2 and Tier 3 Chinese cities where pricing pressure dominates procurement decisions. Benchmark Dynamics at a Glance: First-mover advantage still benefits Roche, but its single-agent approach is aging fast. AstraZeneca/Daiichi are setting the innovation pace with ADCs and global expansion. Mid-tier biotechs like Zymeworks are innovating around HER2 heterogeneity and resistance. Local players in Asia are gaining traction through affordability and biosimilar launches. Global strategy is shifting from monotherapy to carefully layered regimens — often involving diagnostics, immune agents, and patient stratification. Regional Landscape And Adoption Outlook HER2 positive gastric cancer is a global concern — but how it’s diagnosed, treated, and reimbursed varies widely from one region to another. Incidence rates, health system maturity, access to biologics, and even patient referral patterns all play a role in shaping regional dynamics. Here's how adoption is playing out across key geographies. North America The U.S. remains a stronghold for HER2-targeted innovation, especially in clinical trial activity and early drug adoption. HER2 testing is now routine for newly diagnosed gastric and gastroesophageal junction (GEJ) adenocarcinomas in academic and community settings. Trastuzumab-based regimens dominate first-line use, while newer entrants like trastuzumab deruxtecan are rapidly gaining formulary status through expedited FDA reviews. Reimbursement frameworks under Medicare and commercial payers have largely aligned with NCCN guidelines, which endorse HER2 testing and HER2-directed therapy. However, disparities remain: access is smoother in major cancer centers , but rural patients often face delays in both diagnostics and infusion services. The U.S. is also a key R&D hub, with most HER2 gastric trials anchored at leading oncology centers like MD Anderson and Memorial Sloan Kettering. Europe In Europe, uptake is strong in countries with centralized cancer care systems — particularly Germany, France, and the UK. HER2 testing is part of national gastric cancer protocols, and trastuzumab has been integrated into treatment pathways since EMA approval. That said, newer agents like ADCs face variable adoption due to country-specific cost-effectiveness thresholds. Health technology assessment (HTA) agencies, such as NICE in the UK, are cautious about approving high-cost biologics without long-term real-world data. Some Eastern European countries lag behind in both testing infrastructure and biologic drug access, which creates a two-speed market even within the EU. Multinational pharma companies are now tailoring market access strategies country by country, often using real-world evidence to justify pricing. Asia Pacific This is the most dynamic region for HER2 positive gastric cancer, largely because it has the highest gastric cancer incidence in the world. Japan, South Korea, and China collectively account for a significant share of global HER2 gastric cases — and they’re also leading innovation in this space. Japan was one of the earliest adopters of HER2 testing for gastric cancer and continues to be a high-uptake market for both trastuzumab and ADCs. South Korea’s reimbursement system supports biomarker-driven therapy, and clinical trial participation is high. China, while still fragmented, is evolving fast. The country has scaled HER2 testing in urban tertiary centers and is moving toward broader biologics access through provincial reimbursement lists. Domestic pharma players are also launching biosimilars and co-developing HER2 candidates, accelerating affordability. Asia’s big opportunity lies in expanding HER2 access beyond tier-1 cities — and many global and local companies are racing to build distribution and diagnostic networks accordingly. Latin America, Middle East, and Africa (LAMEA) This region remains the most underpenetrated — not due to lack of need, but due to infrastructure and cost barriers. In countries like Brazil and Mexico, HER2 testing is available in urban cancer hospitals, but access to trastuzumab or newer biologics is inconsistent. Out-of-pocket costs are a major barrier, and public insurance systems are slow to incorporate expensive targeted therapies. The Middle East shows a bifurcated picture. The UAE and Saudi Arabia are building specialized oncology centers and increasingly funding HER2-directed therapy. However, access remains limited in North and Sub-Saharan Africa, where basic pathology services are still uneven. NGOs and global cancer alliances are beginning to fund HER2 testing and treatment programs in low-resource settings, but coverage remains patchy. Regional Summary North America leads in early adoption and innovation Europe is mature but price-sensitive, especially for next- gen therapies Asia Pacific is the high-volume growth engine with strong public-private momentum LAMEA is the white space — and the long-term opportunity for scalable, affordable HER2 solutions End-User Dynamics And Use Case In the HER2 positive gastric cancer market, end users aren’t just healthcare providers — they are key decision-makers who determine how and when targeted therapies are initiated. From large academic hospitals to mid-tier oncology clinics, treatment workflows differ significantly based on institutional infrastructure, diagnostic access, and reimbursement environment. Tertiary Cancer Centers These institutions represent the primary point of care for most HER2 positive gastric cancer patients. They typically have in-house pathology labs, streamlined HER2 IHC and FISH testing capabilities, and multidisciplinary tumor boards that can make quick treatment decisions. These centers are also the first to adopt emerging agents like antibody-drug conjugates (ADCs) and participate in combination trials. In many cases, patients are referred here only after diagnosis — which places added pressure on these centers to revalidate HER2 status and start treatment within narrow therapeutic windows. Integration with clinical research units allows them to offer newer drugs before full market availability. These hospitals also serve as data generators — their real-world outcomes often influence national guidelines and payer decisions. Community Oncology Clinics In the U.S., Japan, and parts of Europe, community oncology practices are beginning to offer HER2-targeted treatments, especially as more agents become standard of care. However, most of these clinics rely on external labs for HER2 testing, which can introduce delays. They typically administer trastuzumab and chemotherapy but may refer patients to larger centers for second-line options like T- DXd . Pharmaceutical companies often support these clinics through patient access programs, dosing protocols, and educational resources to ensure adherence to guidelines. For these centers , simplicity and predictability in therapy administration are key. That’s why subcutaneous formulations and shorter infusion times are gaining favor . Diagnostic Laboratories While not administering therapy, diagnostic labs are crucial end users in their own right — especially those performing centralized HER2 testing. Their turnaround time, reporting quality, and interpretive accuracy directly influence treatment selection. Some labs are now bundling HER2 testing with broader NGS panels to capture co-mutations and predict resistance, enabling oncologists to personalize treatment early. Pharmacy and Infusion Networks Hospital pharmacies and infusion centers handle the backend of drug logistics — including acquisition, reimbursement processing, and administration of HER2-targeted agents. ADCs like T- DXd require cold-chain handling and trained infusion staff, which makes integration with pharmacy services critical. In several regions, dedicated infusion slots are now allocated for HER2 positive gastric patients due to the growing complexity of regimens. Use Case Highlight A major cancer institute in South Korea faced a recurring problem: delayed HER2 test results were pushing treatment initiation beyond the recommended 14-day window. To solve this, the hospital partnered with a local diagnostic firm to install an on-site digital pathology scanner with AI-based HER2 scoring. Results were available within 36 hours. This allowed the tumor board to initiate HER2-targeted therapy significantly faster. Over a 12-month pilot, average time-to-treatment dropped by 42%, and treatment adherence rose by nearly 30%. The hospital also reduced the number of patients requiring bridge chemotherapy while waiting for test results. Recent Developments + Opportunities & Restraints Recent Developments (Last 2 Years) Trastuzumab deruxtecan (T- DXd) received expanded FDA approval in 2024 for second-line HER2 positive gastric cancer based on updated survival data from DESTINY-Gastric02 trial. Zanidatamab, a bispecific HER2 antibody from Zymeworks , entered Phase III trials in early 2025 targeting HER2-positive gastroesophageal junction adenocarcinoma patients. China’s NMPA approved a locally developed HER2 biosimilar (HLX02 by Henlius ) for use in gastric cancer in late 2023, expanding regional access. MSKCC and GE Healthcare launched a digital pathology AI pilot for HER2 scoring in gastric biopsy slides, aiming to cut diagnostic delays by 50%. Combination regimens involving trastuzumab, nivolumab, and chemotherapy are being piloted in Europe under EORTC-supported umbrella trials targeting HER2 and PD-1 co-expression. Opportunities First-Line Combination Expansion As evidence grows for HER2 plus PD-1 inhibitors, next-generation regimens could redefine the treatment paradigm from the start — opening the door for dual approvals. HER2 Testing Penetration in Asia and LAMEA Expanding IHC and FISH access in India, Brazil, and sub-Saharan Africa presents a significant growth lever — especially as diagnostic kits become more affordable. Digital Diagnostics and AI-Scoring Adoption of AI-based HER2 interpretation tools could reduce variability and bring HER2 testing to under-resourced hospitals, improving access to precision therapy globally. Restraints Biologic Therapy Cost Burden HER2-targeted drugs, especially ADCs, remain among the most expensive oncology therapies. In many middle-income countries, this limits both adoption and reimbursement. Tumor Heterogeneity and Testing Accuracy HER2 expression in gastric cancer is often heterogeneous, leading to testing challenges and inconsistent treatment response — especially in community settings with limited pathology expertise. 7.1. Report Coverage Table Report Attribute Details Forecast Period 2024 – 2030 Market Size Value in 2024 USD 3.7 Billion Revenue Forecast in 2030 USD 5.5 Billion Overall Growth Rate CAGR of 6.8% (2024 – 2030) Base Year for Estimation 2024 Historical Data 2019 – 2023 Unit USD Million, CAGR (2024 – 2030) Segmentation By Therapy Type, Line of Treatment, Diagnostic Modality, Distribution Channel, Geography By Therapy Type Monoclonal Antibodies, ADCs, TKIs, Immunotherapies By Line of Treatment First-Line, Second-Line, Third-Line & Beyond By Diagnostic Modality IHC, FISH, NGS By Distribution Channel Hospital Pharmacies, Specialty Pharmacies, Infusion Centers By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, Germany, UK, France, China, Japan, South Korea, India, Brazil, Saudi Arabia Market Drivers - Growing adoption of HER2 testing in gastric cancers - Expansion of ADC and combination therapy pipelines - Rising gastric cancer burden in Asia-Pacific Customization Option Available upon request Frequently Asked Question About This Report Q1: How big is the HER2 positive gastric cancer market? A1: The global HER2 positive gastric cancer market is valued at USD 3.7 billion in 2024 and projected to reach USD 5.5 billion by 2030. Q2: What is the CAGR for the HER2 positive gastric cancer market during the forecast period? A2: The market is growing at a 6.8% CAGR from 2024 to 2030. Q3: Who are the major players in the HER2 positive gastric cancer market? A3: Leading companies include Roche, AstraZeneca/Daiichi Sankyo, Zymeworks, Seagen (Pfizer), and Jiangsu Hengrui. Q4: Which region dominates the HER2 positive gastric cancer market? A4: Asia Pacific leads in patient volume and innovation, while North America dominates in early adoption and advanced clinical protocols. Q5: What factors are driving the HER2 positive gastric cancer market? A5: Growth is driven by advancements in targeted therapy, rising HER2 testing adoption, and strong oncology pipelines focused on ADCs and combination regimens. Executive Summary Market Overview Market Attractiveness by Therapy Type, Line of Treatment, Diagnostic Modality, Distribution Channel, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Future Projections (2019–2030) Summary of Market Segmentation by Therapy Type, Line of Treatment, Diagnostic Modality, Distribution Channel, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Therapy Type, Line of Treatment, and Diagnostic Modality Strategic Benchmarking of Key Companies Investment Opportunities in the HER2 Positive Gastric Cancer Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Focus Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Diagnostic, Clinical, and Regulatory Factors Role of Combination Therapies in HER2-Driven Oncology Global HER2 Positive Gastric Cancer Market Analysis By Therapy Type Monoclonal Antibodies Antibody-Drug Conjugates (ADCs) Tyrosine Kinase Inhibitors (TKIs) Immunotherapies By Line of Treatment First-Line Treatment Second-Line Treatment Third-Line & Beyond By Diagnostic Modality Immunohistochemistry (IHC) Fluorescence In Situ Hybridization (FISH) Next-Generation Sequencing (NGS) By Distribution Channel Hospital Pharmacies Specialty Pharmacies Infusion Centers By Region North America Europe Asia-Pacific Latin America Middle East & Africa Regional HER2 Positive Gastric Cancer Market Analysis North America U.S. Canada Europe Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific China Japan South Korea India Rest of Asia-Pacific Latin America Brazil Argentina Rest of Latin America Middle East & Africa Saudi Arabia UAE South Africa Rest of Middle East & Africa Key Players and Competitive Analysis Roche AstraZeneca/Daiichi Sankyo Zymeworks Seagen (Pfizer) Jiangsu Hengrui Innovent Biologics Other Emerging Players Appendix Abbreviations and Terminologies Used in the Report References and Source List List of Tables Market Size by Therapy Type, Line of Treatment, Diagnostic Modality, Distribution Channel, and Region (2024–2030) Regional Market Breakdown by Key Segment (2024–2030) List of Figures Market Dynamics: Drivers, Restraints, Opportunities, and Challenges Regional Snapshot and Growth Forecasts Competitive Landscape and Market Share Distribution Growth Strategies and Pipeline Analysis by Leading Players Segment-Level Growth Forecasts (2024 vs. 2030)